Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Non-Current Assets (2023 - 2025)

Compass Therapeutics' Other Non-Current Assets history spans 3 years, with the latest figure at $568000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $568000.0; the TTM value through Dec 2025 reached $568000.0, changed 0.0%, while the annual FY2025 figure was $568000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $568000.0 at Compass Therapeutics, roughly flat from $568000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $568000.0 in Q3 2024 and bottomed at $320000.0 in Q1 2023.
  • The 3-year median for Other Non-Current Assets is $444000.0 (2023), against an average of $444000.0.
  • The largest YoY upside for Other Non-Current Assets was 77.5% in 2024 against a maximum downside of 0.0% in 2024.
  • A 3-year view of Other Non-Current Assets shows it stood at $320000.0 in 2023, then skyrocketed by 77.5% to $568000.0 in 2024, then changed by 0.0% to $568000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Other Non-Current Assets are $568000.0 (Q4 2025), $568000.0 (Q3 2025), and $568000.0 (Q2 2025).